Research Unit of Medical Senology, European Institute of Oncology, via Ripamonti 435, Milan, Italy.
Breast. 2011 Feb;20(1):34-8. doi: 10.1016/j.breast.2010.06.005. Epub 2010 Jul 16.
To explore the activity of pegylated liposomal doxorubicin (PLD) as neoadjuvant therapy of breast cancer.
The combination of PLD with cisplatin and infusional fluorouracil (CCF) for 8 courses was investigated in patients with primary or recurrent T2-T4a-d N0-3 M0 breast cancer. Patients with ER and/or PgR ≥10% tumors also received letrozole (±triptorelin).
Forty patients entered the study. Four patients had recurrent tumors and 13 had cT4d tumors. Overall, clinical response rate was 77.5% whereas a pathological complete response (pCR) was obtained in 3 patients (7.7%), 4 when considering bilateral tumors. Noticeably 3 pCR were observed among the 10 patients with T4d ER positive tumors (33%). Eleven patients discontinued treatment before completion of the 8 planned courses.
Our results indicated that CCF yielded an appreciable rate of clinical responses in a series of very locally advanced tumors and an unusually high rate of pCR in T4d ER positive tumors, suggesting an enhanced cutaneous activity of PLD.
探讨聚乙二醇脂质体阿霉素（PLD）作为乳腺癌新辅助治疗的活性。
将 PLD 与顺铂和持续输注氟尿嘧啶（CCF）联合应用于 40 例原发性或复发性 T2-T4a-d N0-3 M0 乳腺癌患者。ER 和/或 PgR≥10%肿瘤的患者还接受来曲唑（±曲普瑞林）治疗。
4 例患者有复发性肿瘤，13 例患者有 cT4d 肿瘤。总的来说，临床缓解率为 77.5%，3 例（7.7%）患者获得病理完全缓解（pCR），4 例双侧肿瘤患者获得 pCR。值得注意的是，10 例 T4d ER 阳性肿瘤患者中有 3 例（33%）观察到 pCR。11 例患者在完成 8 个计划疗程前停止治疗。
我们的结果表明，CCF 在一系列非常局部晚期的肿瘤中产生了相当高的临床缓解率，在 T4d ER 阳性肿瘤中产生了异常高的 pCR 率，提示 PLD 具有增强的皮肤活性。
